GeoPharma, Inc. Logo

GeoPharma Announces Fiscal Year 2010 Third Quarter Results Conference Call

| Source: GeoPharma, Inc.

LARGO, Fla., March 1, 2010 (GLOBE NEWSWIRE) -- GeoPharma, Inc. (Nasdaq:GORX) (the "Company") is hosting a conference call on March 2, 2010 at 11 a.m. ET to discuss the Fiscal Year 2010 Third Quarter Results that were previously announced on Feb. 23, 2010. During the call, the company will discuss the Fiscal Year Third Quarter results (The period ended Dec. 31, 2009) and other pertinent business developments. The conference call will be hosted by GeoPharma, Inc. CEO Mihir Taneja and Sr. VP/CFO Carol Dore-Falcone. Participants may dial in 15 minutes before the call is set to begin to register. The dial in number for participants is 1-408-337-0124 . The Conference Confirmation code is 60291243

 Date:	March 2, 2010
 Time:	11:00 AM ET

Listen via Internet:

Schedule this webcast into MS-Outlook calendar (click open when prompted):

Replay of the call will be available from 2 p.m. ET on March 2nd, through Tuesday, March 16th. The Replay of the call may be heard by dialing 706-645-9291. The Replay Pass Code is 60291243. Participants may also choose to listen to the call via webcast through the link in the events and presentations section of the Investor Relations page of the GeoPharma website located at

ABOUT GEOPHARMA, INC.: GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing and Distribution divisions, manufacture, package, and distribute generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide.

The GeoPharma, Inc. logo is available at

This press release may contain statements, which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission. <br><br>This news release was distributed by GlobeNewswire,

SOURCE: GeoPharma, Inc.

GeoPharma, Inc.
Alexander Nachman
727-544-8866 x 249